PDS Biotechnology raises $11.55M in private placement, grants Nant board seats

What happened

On September 7, 2026, PDS Biotechnology Corporation entered into a securities purchase agreement with accredited investors for a private placement. The company agreed to sell units consisting of common stock or pre-funded warrants plus common warrants, with an initial closing expected on or about September 11, 2026.

The initial closing is expected to raise approximately $11.55 million in gross proceeds, with an aggregate of 20,875,220 shares of common stock, 20,009,736 pre-funded warrants, and 20,442,479 common warrants expected to be issued. The share unit purchase price was set at $0.2825, and the pre-funded unit purchase price at $0.28217.

A separate, contingent milestone closing is also part of the agreement. If PDS submits a registrational Phase 3 clinical trial protocol for PDS0301 to the FDA, Nant Capital, LLC and AB Group Ltd. will be obligated to purchase an additional $11 million in securities (with Nant purchasing $10 million and AB Group $1 million) at a per-share price of $0.22.

The company also granted Nant the right to designate two board members (one of whom must be Dr. Patrick Soon-Shiong) as long as Nant owns 15% or more of the company's outstanding common stock. The board was increased from six to eight members effective as of the initial closing date.

Shares surged 36.36% to close at $0.30 on September 8, 2026, with volume exceeding 484 million shares compared to an average of about 1.3 million, suggesting heavy trading activity.

Context

PDS Biotechnology is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and infectious diseases, including its lead candidate PDS0101 and earlier-stage PDS0301.

The filing cites Item 1.01 (material agreement), Item 3.02 (unregistered sales of equity), Item 7.01 (Regulation FD disclosure), and Item 9.01 (financial statements and exhibits). The Regulation FD item is referenced but not detailed in the provided text.

The company will also grant NantWorks, LLC an exclusive option to negotiate an exclusive license for its PDS0101 program for one year, in exchange for a $25,000 payment.

What this means

This 8-K discloses a private placement, which is a sale of securities that is exempt from registration with the SEC under Regulation D. Unlike a public offering, these shares are sold to accredited investors without a prospectus, and the company is not required to file a registration statement for the sale itself, though it has committed to file one for resale.

The structure includes common warrants and pre-funded warrants. Common warrants give the holder the right to buy a share at a set price ($0.22 here) for one year. Pre-funded warrants are essentially shares that are already paid for, except for a nominal exercise price ($0.00033 here), allowing investors to hold voting rights without exceeding ownership caps that would trigger disclosure or other rules.

A milestone closing is a delayed tranche of financing tied to a specific event—here, FDA submission of a Phase 3 protocol for PDS0301. This ties additional capital to a regulatory milestone, reducing upfront dilution.

The board designation right gives Nant influence over governance if its ownership threshold is maintained, which is typical for larger investors.

The high trading volume and price jump suggest strong market reaction, though the filing text does not explain the cause.